Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

“We are thrilled that our Phase 2a data show that a once-daily dose of VTX3232 can safely maintain plasma and CSF levels above the IC 90 for IL-1b for 24 hours in patients with early Parkinson ...

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease.

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- ...

(RTTNews) - Ventyx Biosciences, Inc. (VTYX) announced Tuesday positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage ...

Ventyx Biosciences has shared promising top-line results from a phase 2a study of its investigational central nervous system ...